The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

Episode 198

0:00-38:49

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI data 15:47: How the Ochre-Lexogen partnership began 17:17: Why a specialist partner is essential for scale 18:21: Lexogen delivers on the massive sequencing project 21:50: Why high quality data is crucial 27:02: Lexogen's role in AI discovery 34:51: Future plans and directions This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Deep phenotyping brings accuracy to precision medicine Spatial Transcriptomics: A window into disease Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions

Publisher

Beyond Biotech - the podcast from Labiotech

Published

May 22, 2026

Duration

39 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#drugdiscovery #ochrebio #humandata

The Nile